July 2003
Worldwide Biotech;Jul2003, Vol. 15 Issue 7, p1
Trade Publication
Reports on a patent granted to Cancer Vac Ltd., a subsidiary of Prima Biomed Ltd. in the U.S.


Related Articles

  • License to Test Cancer Vaccines in U.S. a Victory for Cuban Biotechnology. Randal, Judith // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1740 

    Reports that CancerVax Corp., a Cuban biotechnology firm, has been granted permission by the Office of Foreign Assets Control to license three experimental cancer vaccines in the U.S. Interest of the firm to the genetically engineered therapeutic vaccines; Terms of the agreement between Center...

  • NEWS HEADLINES: Biotechnology.  // PharmaWatch: Biotechnology;June 2003, Vol. 2 Issue 6, p16 

    Reports developments in the biotechnology industry as of June 2003. Resumption of patient enrollment in the two international phase III clinical trials of the Canvaxin therapeutic cancer vaccine from CancerVax Corp.; Details of the merger agreement signed by GenVec Inc. and Diacrin Inc.;...

  • Reception Cool, Stock Price Flat for CanverVax IPO. Webb, Marion // San Diego Business Journal;11/3/2003, Vol. 24 Issue 44, p3 

    Reports on the debut of CancerVax Corp. on the Nasdaq Stock Market Inc. stock exchange in San Diego County, California. Value of shares sold by the company; Price of the stock per share; Stage of testing required by the U.S. Food and Drug Administration with the Canvaxin drug developed by the...

  • Qualcomm Insists Junk a Good Investment. Allen, Mike // San Diego Business Journal;5/6/2002, Vol. 23 Issue 18, p8 

    Reports developments on high technology industry as of May 2002 in San Diego, California. Investment of Qualcomm Inc. on non-investment grade corporate bonds; Increase in the venture capital investments of CancerVax Corp. and other companies in the city; Net income reported by Cubic Corp.

  • DC-based vaccines gaining ground. Jesitus, John // Dermatology Times;Feb2005, Vol. 26 Issue 2, p124 

    The article focuses on the development of melanoma vaccines based on dendritic cells (DCs) which is rapidly moving from the lab bench into clinical trials. Among melanoma vaccines now in development, Canvaxin by Cancer Vax Corp. leads the way in terms of clinical testing. At press time, it was...

  • CancerVax ends vaccine.  // Chemical Market Reporter;10/10/2005, Vol. 268 Issue 12, p7 

    Reports on the decision of Cancervax Corp. to discontinue development of its cancer vaccine Canvaxin in Los Angeles, California. Reason for the clinical trial termination; Impact of the cancellation on the company's stocks; Uncertainties on the company's partnership with Serono after the...

  • Experimental Drugs Approved for Licensing.  // Clinical Journal of Oncology Nursing;Dec2004, Vol. 8 Issue 6, p588 

    Reports on the federal permission received by CancerVax Corp. to license three experimental drugs from the Cuban biotech company CIMAB. Indications of the drugs.

  • Preclinical data confirm anti-angiogenic effects of CancerVax monoclonal antibody.  // PharmaWatch: Biotechnology;June 2004, Vol. 3 Issue 6, p7 

    Reports on the release of a preclinical results by CancerVax Corp. that support the anti-angiogenic effects of its H8, a humanized monoclonal antibody to denatured collagen in the U.S. Inhibition of angiogenesis in animal models of choroidal neovascularization; Cause of severe visual loss in...

  • CancerVax Wins Approval. Webb, Marion // San Diego Business Journal;7/19/2004, Vol. 25 Issue 29, p38 

    Reports on the U.S. government approval of a licensing experiment of a drug from Cuba by Cancervax Corp., a biotechnology company. Number of potential products that are approved by the Treasury's Office of Foreign Assets Control; Qualities of the lead candidate drug, SAI-EGF.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics